LG 00034053
Alternative Names: LG-00034053Latest Information Update: 17 May 2024
At a glance
- Originator LG Chem
- Class Antirheumatics
- Mechanism of Action Caspase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Osteoarthritis
Most Recent Events
- 11 Mar 2024 LG Chem completes a Phase-I/II clinical trials in Osteoarthritis in Australia and South Korea (Intra-articular) (NCT05237752)
- 07 Feb 2024 Phase-I/II clinical trials in Osteoarthritis in Australia (Intra-articular) (NCT05237752)
- 27 Apr 2022 Phase-I/II clinical trials in Osteoarthritis in South Korea (Intra-articular) (NCT05237752)